Page last updated: 2024-09-03

valdecoxib and Brain Neoplasms

valdecoxib has been researched along with Brain Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K	1
Darabi, A; Eberstål, S; Fritzell, S; Sandén, E; Siesjö, P; Visse, E	1

Other Studies

2 other study(ies) available for valdecoxib and Brain Neoplasms

Article	Year
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. BMC cancer, 2021, May-03, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway	2021
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Female; Flow Cytometry; Glioma; Granulocyte-Macrophage Colony-Stimulating Factor; Immunoenzyme Techniques; Immunotherapy; Intramolecular Oxidoreductases; Isoxazoles; Mice; Mice, Inbred C57BL; Prostaglandin-E Synthases; Sulfonamides; Tumor Cells, Cultured	2014

Article

Year

COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.

BMC cancer, 2021, May-03, Volume: 21, Issue:1

Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway

2021

Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.

International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Female; Flow Cytometry; Glioma; Granulocyte-Macrophage Colony-Stimulating Factor; Immunoenzyme Techniques; Immunotherapy; Intramolecular Oxidoreductases; Isoxazoles; Mice; Mice, Inbred C57BL; Prostaglandin-E Synthases; Sulfonamides; Tumor Cells, Cultured

2014